Chronic Obstructive Pulmonary Disease

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Jun 10, 2013
popularity not rated yet | comments 0

Latest Spotlight News

People trust typical-looking faces most

Being "average" is often considered a bad thing, but new research suggests that averageness wins when people assess the trustworthiness of a face. The research indicates that, while typical-looking faces ...